RAB22A

Across TCGA pan-cancer cohorts, RAB22A mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated RAB22A data layer compared with 27 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher RAB22A mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated RAB22A expression acts as an unfavorable survival marker, although some lineages such as HNSC and COAD show a favorable association.

HNSC, PDAC, and COAD are the cancer types where RAB22A mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Median	All	0.788	0.520	<.001	59	view →
PDAC	DFS	Tertile	III,IV	0.249	0.967	<.001	50	view →
COAD	DFS	Tertile	All	1.000	0.921	.038	12	view →
LUAD	OS	Tertile	III,IV	0.840	0.269	.011	10	view →
CCRCC	OS	Quartile	III,IV	0.382	0.828	.013	8	view →
GBM	DFS	Quartile	All	0.884	0.664	.007	7	view →
LSCC	DFS	Tertile	All	0.590	1.000	.018	5	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

RAB22A–HNSC (DFS)

Open the HNSC breakdown →